Azitra Inc(US:AZTR) Prnewswire·2026-02-06 21:15Core Viewpoint - Azitra, Inc. has adjourned its Special Meeting originally scheduled for February 6, 2026, due to insufficient shareholder participation, with a new date set for March 6, 2026, to solicit additional votes on key proposals [1]. Group 1: Special Meeting Details - The Special Meeting was adjourned because only approximately 13% of the outstanding shares entitled to vote were represented, falling short of the required 33 1/3% quorum [1]. - The Reconvened Special Meeting will take place on March 6, 2026, at 11:00 a.m. Eastern Time, and will continue to be held in a virtual format [1]. - Stockholders are encouraged to vote their shares before the new deadline of March 6, 2026, at 10:59 a.m. Eastern Time [1]. Group 2: Proposals for Vote - Proposal One seeks approval for the issuance of more than 19.99% of the company's outstanding shares, which includes shares underlying warrants as per the Securities Purchase Agreement with Alumni Capital LP [1]. - Proposal Two allows for the adjournment of the Special Meeting if necessary to solicit additional proxies if there are insufficient votes [1]. Group 3: Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on innovative therapies for precision dermatology, with its lead program, ATR-12, targeting Netherton syndrome, a rare skin disease [1]. - The company also has an advanced program, ATR-04, aimed at treating EGFR inhibitor-associated rash, which affects approximately 150,000 people in the U.S. [1]. - Azitra's programs utilize a proprietary platform of engineered proteins and topical live biotherapeutic products, supported by artificial intelligence and machine learning technology [1].